Cover Image
市場調查報告書

過敏性鼻炎結膜炎:開發中產品分析

Allergic Rhino-Conjunctivitis - Pipeline Review, H2 2015

出版商 Global Markets Direct 商品編碼 255930
出版日期 內容資訊 英文 82 Pages
訂單完成後即時交付
價格
Back to Top
過敏性鼻炎結膜炎:開發中產品分析 Allergic Rhino-Conjunctivitis - Pipeline Review, H2 2015
出版日期: 2015年09月16日 內容資訊: 英文 82 Pages
簡介

過敏性鼻炎結膜炎是最常發生的過敏性疾病。主要的症狀有鼻塞和鼻涕,流眼淚,眼皮腫,口·喉嚨·耳朵·臉部發癢,咳嗽等。主要的易罹病素質有抽煙和污染物質,煤煙,化學藥品等。主要的治療藥有抗組織胺藥物和皮質類固醇,鼻塞藥等。

本報告提供全球各國治療過敏性鼻炎結膜炎所用的開發中產品之開發情形相關分析,提供您開發中產品的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等調查,並將結果概述為以下內容。

簡介

  • 分析範圍

過敏性鼻炎結膜炎概要

治療藥的開發

  • 過敏性鼻炎結膜炎開發中產品:概要

各企業正在開發的過敏性鼻炎結膜炎治療藥

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品

過敏性鼻炎結膜炎治療藥:開發中的產品一覽 (各企業)

過敏性鼻炎結膜炎開發治療藥的企業

  • ALK-Abello A/S
  • Allergopharma Joachim Ganzer KG
  • Allergy Therapeutics Plc
  • Bial
  • BioTech Tools s.a.
  • Circassia Pharmaceuticals Plc
  • Greer Laboratories, Inc.
  • HAL Allergy BV
  • Immunomic Therapeutics, Inc.
  • Laboratorios LETI S.L.
  • Oxagen Limited
  • Stallergenes S.A.

過敏性鼻炎結膜炎:治療藥的評估

  • 單劑治療藥的情況
  • 標的別
  • 各作用機制
  • 各投藥法
  • 各分子類型

藥物簡介

  • AL-0704rP
    • 產品概要
    • 功能機制
    • 研究開發 (R&D) 的發展情形
  • 過敏性鼻炎·過敏性鼻炎結膜炎的過敏原
  • 過敏性鼻炎·過敏性鼻炎結膜炎·過敏性氣喘的過敏原
  • 白樺花粉的過敏性鼻炎·過敏性鼻炎結膜炎的過敏原
  • 白樺花粉的過敏性鼻炎結膜炎的過敏原
  • 亞利桑那杉 (Arizona cypress) 花粉的過敏性鼻炎結膜炎的過敏原
  • 鄴扁虱的過敏性鼻炎結膜炎的過敏原
  • 牧草花粉的過敏性鼻炎·過敏性鼻炎結膜炎的過敏原
  • 鈉沙蓬 鉀肥 (Salsola Kali) 花粉的過敏性鼻炎結膜炎的過敏原
  • Allergovac
  • ASP-4070
  • gp-ASIT
  • MK-8237
  • OC-000459
  • 橄欖樹花粉萃取物
  • Pollinex Quattro Grass
  • 豬菜花粉萃取物
  • rBet v1
  • rBet v1-FV
  • rPhleum
  • 過敏性鼻炎結膜炎·鄴扁虱過敏疫苗
  • 氣喘·牧草花粉症·過敏性鼻炎結膜炎疫苗

過敏性鼻炎結膜炎治療藥:最新的藥物簡介

過敏性鼻炎結膜炎治療藥:開發暫停的產品

過敏性鼻炎結膜炎治療藥:開發中止的產品

過敏性鼻炎結膜炎相關產品的開發的里程碑

  • 值得注意的最新趨勢·新聞稿 (全6件)

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC7101IDB

Summary

Global Markets Direct's, 'Allergic Rhino-Conjunctivitis - Pipeline Review, H2 2015', provides an overview of the Allergic Rhino-Conjunctivitis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Allergic Rhino-Conjunctivitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Allergic Rhino-Conjunctivitis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Allergic Rhino-Conjunctivitis
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Allergic Rhino-Conjunctivitis and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Allergic Rhino-Conjunctivitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Allergic Rhino-Conjunctivitis pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Allergic Rhino-Conjunctivitis
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Allergic Rhino-Conjunctivitis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Allergic Rhino-Conjunctivitis Overview
  • Therapeutics Development
    • Pipeline Products for Allergic Rhino-Conjunctivitis - Overview
  • Allergic Rhino-Conjunctivitis - Therapeutics under Development by Companies
  • Allergic Rhino-Conjunctivitis - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
  • Allergic Rhino-Conjunctivitis - Products under Development by Companies
  • Allergic Rhino-Conjunctivitis - Companies Involved in Therapeutics Development
    • ALK-Abello A/S
    • Allergopharma Joachim Ganzer KG
    • Allergy Therapeutics Plc
    • Bial - Portela & Ca, S.A.
    • BioTech Tools s.a.
    • Circassia Pharmaceuticals Plc
    • Greer Laboratories, Inc.
    • HAL Allergy BV
    • Immunomic Therapeutics, Inc.
    • Laboratorios LETI S.L.
    • Oxagen Limited
    • Stallergenes S.A.
  • Allergic Rhino-Conjunctivitis - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • AL-0704rP - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Allergen for Allergic Rhinitis and Allergic Rhino-Conjunctivitis - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Allergen for Allergic Rhinitis, Allergic Rhino-Conjunctivitis and Allergic Asthma - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Allergen for Birch Pollen Induced Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Allergen for Birch Pollen Induced Allergic Rhinoconjunctivitis - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Allergen for Cupressus Arizonica Pollen Induced Allergic Rhino-Conjunctivitis - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Allergen for House Dust Mites Induced Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Allergen for Pollen Grass Allergy Induced Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Allergen for Salsola Kali Pollen Induced Allergic Rhinoconjunctivitis - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Allergovac - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ASP-4070 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • gp-ASIT - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MK-8237 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • OC-000459 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Olea Europaea Pollen Extract - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Pollinex Quattro Grass - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Ragweed Pollen Extract - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • rBet v1 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • rBet v1-FV - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • rPhleum - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Vaccine for Allergic Rhino-Conjunctivitis and House Dust Mite Allergy - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Vaccine for Asthma, Grass Pollen Allergy and Allergic Rhino-Conjunctivitis - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Allergic Rhino-Conjunctivitis - Recent Pipeline Updates
  • Allergic Rhino-Conjunctivitis - Dormant Projects
  • Allergic Rhino-Conjunctivitis - Discontinued Products
  • Allergic Rhino-Conjunctivitis - Product Development Milestones
    • Featured News & Press Releases
      • Jun 09, 2014: ALK presents Phase III data on house dust mite SLIT-tablet at EAACI Annual Congress in Copenhagen
      • May 18, 2014: BioTech Tools will be present at the EAACI congress
      • Mar 10, 2014: GREER Investigational Sublingual Allergy Immunotherapy Liquid (SAIL) for Short Ragweed Allergies Phase III Data Published in Journal of Allergy and Clinical Immunology
      • Apr 09, 2013: Inflamax Research Chosen to Conduct a Multicenter Environmental Exposure Chamber Phase 3 Study of Ultrashort Grass Allergy Vaccine by Allergy Therapeutics
      • Mar 20, 2012: HAL Allergy Completes Patient Enrollment For Phase II Trial With PURETHAL Mites
      • Nov 28, 2011: Allergy Therapeutics Submits Complete Response To PEI In Germany And Clinical Study Protocol To FDA
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Allergic Rhino-Conjunctivitis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Comparative Analysis by Late Stage Development, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Products under Development by Companies, H2 2015
  • Products under Development by Companies, H2 2015 (Contd..1)
  • Allergic Rhino-Conjunctivitis - Pipeline by ALK-Abello A/S, H2 2015
  • Allergic Rhino-Conjunctivitis - Pipeline by Allergopharma Joachim Ganzer KG, H2 2015
  • Allergic Rhino-Conjunctivitis - Pipeline by Allergy Therapeutics Plc, H2 2015
  • Allergic Rhino-Conjunctivitis - Pipeline by Bial - Portela & Ca, S.A., H2 2015
  • Allergic Rhino-Conjunctivitis - Pipeline by BioTech Tools s.a., H2 2015
  • Allergic Rhino-Conjunctivitis - Pipeline by Circassia Pharmaceuticals Plc, H2 2015
  • Allergic Rhino-Conjunctivitis - Pipeline by Greer Laboratories, Inc., H2 2015
  • Allergic Rhino-Conjunctivitis - Pipeline by HAL Allergy BV, H2 2015
  • Allergic Rhino-Conjunctivitis - Pipeline by Immunomic Therapeutics, Inc., H2 2015
  • Allergic Rhino-Conjunctivitis - Pipeline by Laboratorios LETI S.L., H2 2015
  • Allergic Rhino-Conjunctivitis - Pipeline by Oxagen Limited, H2 2015
  • Allergic Rhino-Conjunctivitis - Pipeline by Stallergenes S.A., H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Stage and Target, H2 2015
  • Number of Products by Stage and Mechanism of Action, H2 2015
  • Number of Products by Stage and Route of Administration, H2 2015
  • Number of Products by Stage and Molecule Type, H2 2015
  • Allergic Rhino-Conjunctivitis Therapeutics - Recent Pipeline Updates, H2 2015
  • Allergic Rhino-Conjunctivitis - Dormant Projects, H2 2015
  • Allergic Rhino-Conjunctivitis - Discontinued Products, H2 2015

List of Figures

  • Number of Products under Development for Allergic Rhino-Conjunctivitis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Comparative Analysis by Late Stage Development, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Top 10 Targets, H2 2015
  • Number of Products by Stage and Top 10 Targets, H2 2015
  • Number of Products by Top 10 Routes of Administration, H2 2015
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2015
  • Number of Products by Top 10 Molecule Types, H2 2015
  • Number of Products by Stage and Top 10 Molecule Types, H2 2015
Back to Top